Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality

Abstract

As advances in risk assessment facilitate identification of women with increased risk of ER-negative breast cancer, additional mortality reductions could be realized through more frequent targeted screening, provided these benefits are balanced against screening harms.